Literature DB >> 23561259

Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.

Koji Tamai1, Kazuma Nagata, Kyoko Otsuka, Atsushi Nakagawa, Ryo Tachikawa, Kojiro Otsuka, Nobuyuki Katakami, Keisuke Tomii.   

Abstract

Crizotinib-an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-is effective in non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-positive lung adenocarcinoma who was administered crizotinib via nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes, with positive results. This case indicates that patients with ALK-positive NSCLC may successfully be treated with crizotinib via nasogastric or PEG tubes. This approach can even be used as a salvage treatment in patients with poor prognoses.
Copyright © 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23561259     DOI： 10.1016/j.resinv.2012.12.001

Source DB:  PubMed          Journal:  Respir Investig        ISSN： 2212-5345


  5 in total

1.  Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.

Authors:  Hisashi Tanaka; Kageaki Taima; Takeshi Morimoto; Kunihiko Nakamura; Yoshihito Tanaka; Masamichi Itoga; Shingo Takanashi; Ken Okumura
Journal:  BMC Res Notes       Date:  2016-03-17

2.  ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.

Authors:  Vanita Noronha; Anant Ramaswamy; Vijay M Patil; Amit Joshi; Anuradha Chougule; Subhadha Kane; Rajiv Kumar; Arvind Sahu; Vipul Doshi; Lingaraj Nayak; Abhishek Mahajan; Amit Janu; Kumar Prabhash
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

3.  Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status.

Authors:  Osamu Kanai; Young Hak Kim; Koichi Nakatani; Kohei Fujita; Tadashi Mio
Journal:  Clin Case Rep       Date:  2017-04-26

4.  Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer.

Authors:  Ahmed Mohieldin; Ayman Rasmy; Mohamed Ashour; Muath Al-Nassar; Rola H Ali; Fahad G El-Enezi
Journal:  Cancer Manag Res       Date:  2018-11-29       Impact factor: 3.989

5.  Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors.

Authors:  Amanda J W Gibson; Adrian Box; Michelle L Dean; Anifat A Elegbede; Desiree Hao; Randeep Sangha; D Gwyn Bebb
Journal:  JTO Clin Res Rep       Date:  2021-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.